Farmaforce Limited provides contract sales services to the pharmaceutical industry in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.051|
|52 Week High||AU$0.049|
|52 Week Low||AU$0.10|
|1 Month Change||0%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||-57.50%|
|5 Year Change||-68.13%|
|Change since IPO||-84.06%|
Recent News & Updates
|FFC||AU Healthcare||AU Market|
Return vs Industry: Insufficient data to determine how FFC performed against the Australian Healthcare industry.
Return vs Market: Insufficient data to determine how FFC performed against the Australian Market.
Stable Share Price: Insufficient data to determine FFC's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine FFC's volatility change over the past year.
About the Company
Farmaforce Limited provides contract sales services to the pharmaceutical industry in Australia. The company operates in two segments, Contract Sales and Marketing Services to External Customers; and Services to Related Parties. It also offers sales, data, and medical affairs solutions.
Farmaforce Fundamentals Summary
|FFC fundamental statistics|
Is FFC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FFC income statement (TTM)|
|Cost of Revenue||AU$10.47m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0075|
|Net Profit Margin||-8.38%|
How did FFC perform over the long term?See historical performance and comparison
Is Farmaforce undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FFC (A$0.05) is trading below our estimate of fair value (A$2.27)
Significantly Below Fair Value: FFC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FFC is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: FFC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FFC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FFC has negative assets, so we can't compare its PB Ratio to the AU Healthcare industry average.
How is Farmaforce forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Farmaforce has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Farmaforce performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FFC is currently unprofitable.
Growing Profit Margin: FFC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FFC is unprofitable, but has reduced losses over the past 5 years at a rate of 31.2% per year.
Accelerating Growth: Unable to compare FFC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FFC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: FFC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Farmaforce's financial position?
Financial Position Analysis
Short Term Liabilities: FFC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: FFC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: FFC is debt free.
Reducing Debt: FFC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable FFC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: FFC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 60.6% per year.
What is Farmaforce current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FFC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FFC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FFC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FFC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FFC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
George Syrmalis (55 yo)
Dr. George Syrmalis, M.D., Ph D., FACNP, MAAPP, has been Chief Executive Officer at FarmaForce Limited since November 24, 2015 and has been its Executive Director since November 24, 2015. He has been Chair...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD71.07K) is below average for companies of similar size in the Australian market ($USD301.95K).
Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.
Experienced Board: FFC's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Farmaforce Limited's employee growth, exchange listings and data sources
- Name: Farmaforce Limited
- Ticker: FFC
- Exchange: ASX
- Founded: 2014
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$6.665m
- Shares outstanding: 130.68m
- Website: https://www.farmaforce.com.au
- Farmaforce Limited
- 85 Castlereagh Street
- Level 9
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:02|
|End of Day Share Price||2021/09/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.